» Articles » PMID: 23260855

Antimüllerian Hormone Levels Decrease in Women Using Combined Contraception Independently of Administration Route

Overview
Journal Fertil Steril
Date 2012 Dec 25
PMID 23260855
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare the effects of continuous use of oral (OC), transdermal, and vaginal combined contraceptives on the pituitary-ovarian axis and inhibition of follicular development.

Design: Spin-off study of a prospective, randomized trial.

Setting: University clinic.

Patient(s): Forty-two of 54 healthy women completed the study.

Intervention(s): Treatment with combined OCs (ethinyl E2 [EE] and desogestrel), transdermal patches (EE and norelgestromin), or vaginal rings (EE and etonogestrel) for 9 weeks continuously. Blood sampling was performed before and at 5 and 9 weeks of treatment.

Main Outcome Measure(s): Changes in serum hormone levels induced by combined contraceptives.

Result(s): Serum antimüllerian hormone (AMH), FSH, inhibin B, LH, and E2 levels had decreased significantly in all study groups after 9 weeks of treatment. Significant declines were already detected after 5 weeks' use of combined contraceptives with regard to all hormone levels apart from those of serum AMH, where the decrease between baseline and 5 weeks was only moderate. Between groups, serum levels of AMH, inhibin B, LH, and E2 were comparable at baseline and after 5 and 9 weeks of treatment.

Conclusion(s): The decrease of serum AMH levels during the use of all combined contraceptives indicates that folliculogenesis is arrested independently of administration route.

Clinical Trial Registration Number: NCT01087879.

Citing Articles

Ovarian reserve in patients with Sjögren's syndrome: a cross-sectional study.

Mandosi C, Matys V, Deroma M, Del Negro V, Merlino L, Mariani M Clin Rheumatol. 2024; 44(1):319-325.

PMID: 39576415 PMC: 11729113. DOI: 10.1007/s10067-024-07241-7.


Inter-cycle variability of anti-Müllerian hormone: implications for predicting controlled ovarian stimulation cycle outcomes.

Sukur Y, Aslan B, Kaplan N, Dogru M, Ozmen B, Sonmezer M J Ovarian Res. 2024; 17(1):209.

PMID: 39456057 PMC: 11515343. DOI: 10.1186/s13048-024-01517-x.


Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis.

Piltonen T, Viita-Aho J, Saarela U, Melin J, Forslund M Semin Reprod Med. 2024; 42(1):49-59.

PMID: 38776986 PMC: 11257749. DOI: 10.1055/s-0044-1786731.


Diminished Ovarian Reserve in Endometriosis: Insights from In Vitro, In Vivo, and Human Studies-A Systematic Review.

Tan Z, Gong X, Wang C, Zhang T, Huang J Int J Mol Sci. 2023; 24(21).

PMID: 37958954 PMC: 10647261. DOI: 10.3390/ijms242115967.


Potential biomarkers to predict return to fertility after discontinuation of female contraceptives-looking to the future.

Cordova-Gomez A, Wong A, Sims L, Doncel G, Dorflinger L Front Reprod Health. 2023; 5:1210083.

PMID: 37674657 PMC: 10477712. DOI: 10.3389/frph.2023.1210083.